MOONLAKE IMMUNOTHERAPEUTICS Research and Development Expense
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Research and Development Expense of $50.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS research and development expense for the quarter ending 2026-06-30 was $50.22M, a 0.92% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS research and development expense for the quarter ending 2026-03-31 was $54.52M, a 49.52% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS research and development expense for the quarter ending 2025-12-31 was $56.01M, a 38.77% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS research and development expense for the quarter ending 2025-09-30 was $60.63M, a 69.67% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS research and development expense for fiscal 2025 was $202.86M, a 79.89% increase from fiscal 2024.
- MOONLAKE IMMUNOTHERAPEUTICS research and development expense for fiscal 2024 was $112.77M, a 254.60% increase from fiscal 2023.
- MOONLAKE IMMUNOTHERAPEUTICS research and development expense for fiscal 2023 was $31.80M, a 24.37% decline from fiscal 2022.
- MOONLAKE IMMUNOTHERAPEUTICS research and development expense for fiscal 2022 was $42.05M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 10 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $50.22M 10-Q · filed 2026-08-10 | $104.74M 10-Q · filed 2026-08-10 | $160.74M derived: sum of 3 quarters · filed 2026-08-10 | $221.38M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2026-03-31 | $54.52M 10-Q · filed 2026-05-11 | $110.52M derived: sum of 2 quarters · filed 2026-05-11 | $171.16M derived: sum of 3 quarters · filed 2026-05-11 | $220.92M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-12-31 | $56.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $116.64M derived: sum of 2 quarters · filed 2026-02-25 | $166.40M derived: sum of 3 quarters · filed 2026-08-10 | $202.86M 10-K · filed 2026-02-25 | |||||
| 2025-09-30 | $60.63M 10-Q · filed 2025-11-05 | $110.40M derived: sum of 2 quarters · filed 2026-08-10 | $146.86M 10-Q · filed 2025-11-05 | $187.22M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-06-30 | $49.76M 10-Q · filed 2026-08-10 | $86.22M 10-Q · filed 2026-08-10 | $126.58M derived: sum of 3 quarters · filed 2026-08-10 | $162.32M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-03-31 | $36.46M 10-Q · filed 2026-05-11 | $76.82M derived: sum of 2 quarters · filed 2026-05-11 | $112.55M derived: sum of 3 quarters · filed 2026-05-11 | $136.22M derived: sum of 4 quarters · filed 2026-05-11 | |||||
| 2024-12-31 | $40.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $76.09M derived: sum of 2 quarters · filed 2026-02-25 | $99.76M derived: sum of 3 quarters · filed 2026-02-25 | $112.77M 10-K · filed 2026-02-25 | $112.77M 10-K · filed 2025-02-26 | ||||
| 2024-09-30 | $35.74M 10-Q · filed 2025-11-05 | $35.74M 10-Q · filed 2024-11-07 | $59.40M derived: sum of 2 quarters · filed 2025-11-05 | $72.41M 10-Q · filed 2025-11-05 | $72.41M 10-Q · filed 2024-11-07 | $80.51M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $23.66M 10-Q · filed 2025-08-05 | $23.66M 10-Q · filed 2024-08-07 | $36.68M 10-Q · filed 2025-08-05 | $36.68M 10-Q · filed 2024-08-07 | $44.77M derived: sum of 3 quarters · filed 2026-02-25 | $52.36M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $13.01M 10-Q · filed 2025-05-12 | $13.01M 10-Q · filed 2024-05-07 | $21.11M derived: sum of 2 quarters · filed 2026-02-25 | $28.70M derived: sum of 3 quarters · filed 2026-02-25 | $37.40M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $8.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.68M derived: sum of 2 quarters · filed 2026-02-25 | $24.39M derived: sum of 3 quarters · filed 2026-02-25 | $31.80M 10-K · filed 2026-02-25 | $31.80M 10-K · filed 2024-02-29 | ||||
| 2023-09-30 | $7.59M 10-Q · filed 2024-11-07 | $16.29M derived: sum of 2 quarters · filed 2024-11-07 | $23.70M 10-Q · filed 2024-11-07 | $35.07M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-06-30 | $8.70M 10-Q · filed 2024-08-07 | $16.12M 10-Q · filed 2024-08-07 | $27.49M derived: sum of 3 quarters · filed 2025-02-26 | $36.51M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-03-31 | $7.42M 10-Q · filed 2024-05-07 | $18.78M derived: sum of 2 quarters · filed 2025-02-26 | $27.81M derived: sum of 3 quarters · filed 2025-02-26 | $39.21M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2022-12-31 | $11.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $20.39M derived: sum of 2 quarters · filed 2025-02-26 | $31.79M derived: sum of 3 quarters · filed 2025-02-26 | $42.05M 10-K · filed 2025-02-26 | |||||
| 2022-09-30 | $9.02M 10-Q · filed 2023-11-14 | $20.42M derived: sum of 2 quarters · filed 2023-11-14 | $30.68M 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | $11.40M 10-Q · filed 2023-08-10 | $21.66M 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | $10.45M 10-Q · filed 2023-05-11 | ||||||||
| 2021-12-31 | $35.53M 10-K · filed 2023-03-20 | ||||||||
| 2021-09-30 | $669.53K 10-Q · filed 2022-11-14 | $30.54M derived: sum of 2 quarters · filed 2022-11-14 | $30.54M 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $29.87M 10-Q · filed 2022-08-12 | $29.87M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |